Ryan Halsted
Stock Analyst at RBC Capital
(0.44)
# 4,035
Out of 4,396 analysts
71
Total ratings
39.5%
Success rate
-8.3%
Average return
Main Sectors:
Stocks Rated by Ryan Halsted
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Reiterated: Buy | $215 | $189.85 | +13.25% | 3 | Jun 4, 2026 | |
| HQY HealthEquity | Reiterated: Buy | $108 | $89.23 | +21.04% | 2 | Jun 3, 2026 | |
| ICLR ICON Public Limited Company | Maintained: Hold | $123 → $126 | $151.82 | -17.01% | 2 | May 28, 2026 | |
| PHR Phreesia | Maintained: Buy | $19 | $9.29 | +104.52% | 5 | May 27, 2026 | |
| SHC Sotera Health Company | Reiterated: Buy | $24 | $16.53 | +45.19% | 8 | May 22, 2026 | |
| DOCS Doximity | Maintained: Buy | $44 → $28 | $20.45 | +36.92% | 7 | May 14, 2026 | |
| EVH Evolent Health | Reiterated: Hold | $3 | $4.72 | -36.44% | 4 | May 7, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $31 | $22.17 | +39.83% | 6 | May 7, 2026 | |
| MDLN Medline | Reiterated: Buy | $53 | $36.01 | +47.18% | 5 | May 7, 2026 | |
| IQV IQVIA Holdings | Reiterated: Buy | $221 | $186.25 | +18.66% | 4 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $19.17 | +129.53% | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $522 → $484 | $466.79 | +3.69% | 4 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 → $24 | $21.31 | +12.62% | 3 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $23 | $26.00 | -11.54% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $12.86 | n/a | 4 | Jan 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $35.66 | n/a | 1 | Oct 6, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $71.89 | n/a | 1 | Sep 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 | $155.25 | n/a | 3 | May 12, 2016 |
Charles River Laboratories International
Jun 4, 2026
Reiterated: Buy
Price Target: $215
Current: $189.85
Upside: +13.25%
HealthEquity
Jun 3, 2026
Reiterated: Buy
Price Target: $108
Current: $89.23
Upside: +21.04%
ICON Public Limited Company
May 28, 2026
Maintained: Hold
Price Target: $123 → $126
Current: $151.82
Upside: -17.01%
Phreesia
May 27, 2026
Maintained: Buy
Price Target: $19
Current: $9.29
Upside: +104.52%
Sotera Health Company
May 22, 2026
Reiterated: Buy
Price Target: $24
Current: $16.53
Upside: +45.19%
Doximity
May 14, 2026
Maintained: Buy
Price Target: $44 → $28
Current: $20.45
Upside: +36.92%
Evolent Health
May 7, 2026
Reiterated: Hold
Price Target: $3
Current: $4.72
Upside: -36.44%
Privia Health Group
May 7, 2026
Reiterated: Buy
Price Target: $31
Current: $22.17
Upside: +39.83%
Medline
May 7, 2026
Reiterated: Buy
Price Target: $53
Current: $36.01
Upside: +47.18%
IQVIA Holdings
May 5, 2026
Reiterated: Buy
Price Target: $221
Current: $186.25
Upside: +18.66%
Apr 29, 2026
Reiterated: Buy
Price Target: $44
Current: $19.17
Upside: +129.53%
Apr 23, 2026
Reiterated: Buy
Price Target: $522 → $484
Current: $466.79
Upside: +3.69%
Apr 22, 2026
Reiterated: Hold
Price Target: $22 → $24
Current: $21.31
Upside: +12.62%
Apr 13, 2026
Maintained: Hold
Price Target: $23
Current: $26.00
Upside: -11.54%
Jan 12, 2017
Upgraded: Buy
Price Target: n/a
Current: $12.86
Upside: n/a
Oct 6, 2016
Reiterated: Hold
Price Target: n/a
Current: $35.66
Upside: n/a
Sep 9, 2016
Reiterated: Hold
Price Target: n/a
Current: $71.89
Upside: n/a
May 12, 2016
Reiterated: Hold
Price Target: $22
Current: $155.25
Upside: n/a